Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FINESSE trial of finasteride added to active surveillance for localized prostate cancer
ISRCTN16867955Phase 3Active, not recruiting
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
- Start
- Aug 2022
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of finasteride in prostate cancer (PCa) (2 arms), sponsored by Sheffield Teaching Hospitals NHS Foundation Trust. Primary endpoint: Adherence to active surveillance. Started Aug 2022; status: active, not recruiting.
02
Drugs
finasteride
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ISRCTN16867955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN16867955.